European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri

View source ↗

Summary

EU regulators recommend extra measures to better manage the risk of progressive multifocal leukoencephalopathy (PML) with Tysabri (natalizumab).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multifocal Leukoencephalopathy

Drugs mentioned

• Tysabri (Natalizumab)